91制片厂

Jeffrey Halpern, an assistant professor of chemical engineering at 91制片厂, is working to address a prevalent mental health challenge: major depressive disorder (MDD), which frequently goes unrecognized and undiagnosed in the 16.1 million Americans who suffer from it. But the path from the lab to the doctor鈥檚 office can be a long one, especially for researchers working in higher education.

That鈥檚 why Halpern, along with four other distinguished junior investigators, will be receiving support through 91制片厂鈥檚 new Center of Integrated Biomedical and Bioengineering Research (CIBBR). The center, which is funded by a 铿乿e-year, $10 million Center of Biomedical Research Excellence (COBRE) grant from the National Institutes of Health (NIH), will accelerate the translation of their basic biomedical and bioengineering research into actual innovative tools and treatments that improve human health.

Halpern and his team are developing the 铿乺st point-of-care diagnostic sensor that can accurately detect the chemical pro铿乴e of diseases in patients鈥� drawn blood. His goal is to produce a low-cost, high-throughput tool that can diagnose MDD in the doctor鈥檚 office, leading to swifter treatment and better patient outcomes. The technology may one day be used to diagnose other psychiatric diseases, neurological diseases and cancers.

While Halpern is designing his sensors to function outside the body, fellow junior investigator and assistant professor of electrical and computer engineering Edward Song is developing sensors to help clinical researchers monitor the behavior of multiple neurotransmitters inside the brain. The information gained from Song鈥檚 sensor will help unravel the complex root causes of neurological diseases and disorders such as Alzheimer鈥檚 and Parkinson鈥檚, paving the way for earlier diagnosis and new clinical approaches.

Unlocking brain functions at the molecular level is also the goal of Xuanmao Chen鈥檚 research. Chen, an assistant professor of neurobiology, has discovered an enzyme that, when it undergoes a speci铿乧 mutation, causes both obesity and depression. As a part of the CIBBR, he is working to determine the cause of the mutation and develop therapeutic interventions that prevent it from happening.

While an understanding of brain chemistry will solve many human health issues, Sergey Charntikov says there鈥檚 a pressing crisis 鈥� addiction 鈥� that requires a different tack. The assistant professor of psychology is investigating the role environmental stimuli play among smokers, and he believes this new approach, which doesn鈥檛 focus on nicotine鈥檚 addictive chemical properties, will lead to more effective individualized treatments and better long-term outcomes.

Among recent medical innovations, biofabrication offers some of the most exciting human health impacts. Advances in tissue regeneration mean that, someday, waiting lists for donated organs and arti铿乧ial bones made from metal alloys will be relegated to the annals of medical history. At the CIBBR, Kyung Jae Jeong is working to hasten the arrival of that day. Jeong, an assistant professor of chemical engineering, is developing implantable, temporary scaffolds that work with patients鈥� cells and biological signals to regenerate an organ or repair damaged tissue or bone.

听

The main challenge, Jeong explains, is creating an implantable device that won鈥檛 be rejected by the body; he and his team are working to design scaffolds that will be accepted by a patient鈥檚 immune system. Jeong鈥檚 lab will help supply a skilled workforce for federally funded biofabrication programs like the Advanced Regenerative Manufacturing Institute in Manchester.

This COBRE grant caps a decade of 91制片厂 supporting interdisciplinary research and teaching in bioengineering and biomedicine and making strategic investments in instrumentation, infrastructure and faculty.
听

鈥淲e鈥檙e focused on supporting the best biomedical and bioengineering research on campus and helping the researchers think about their work for its clinical, translational medicine and commercialization potential,鈥� says Rick Cote, professor and chair of the department of molecular, cellular and biomedical sciences. 鈥淚t鈥檚 a very powerful opportunity to bring together biomedical and bioengineering researchers and promote their interactions and collaborations with each other, as well as providing avenues to work with clinical researchers at Dartmouth College鈥檚 Geisel School of Medicine and elsewhere.鈥�

Cote, who is the principal investigator for the award, will direct the CIBBR with Kelley Thomas, Hubbard Professor of Genomics and director of the Hubbard Center for Genome Studies, Don Wojchowski, 91制片厂 professor of biomedical sciences, and Steven Fiering, professor of microbiology and immunology at Dartmouth.

Rick Cote Receives Distinguished Professor Award

Watch

In addition to interdisciplinary collaborations, the investigators will bene铿乼 from the acquisition of new instrumentation, including a laser scanning confocal microscope and an X-ray photon spectrometer, and from a comprehensive mentoring program that will prepare them to compete successfully for their own independent research grants.

The grant will also fund undergraduate and graduate researchers working in all 铿乿e labs, giving 91制片厂 students hands-on access to some of the most leading-edge research on campus and important experience working under an NIH-funded project.

The NIH award is the 铿乺st of three 铿乿e-year grants available under the NIH COBRE program. But for now, the primary focus is the success of the research projects led by Charntikov, Halpern, Jeong, Chen and Song. Their ability to secure independent funding and 鈥済raduate鈥� from the center, says Cote, will be the ultimate measure of the CIBBR鈥檚 achievement. As for the 铿乿e junior investigators, they have eagerly begun working on their CIBBR-sponsored research projects.

鈥淭he grant is an invaluable opportunity for researchers early in their careers,鈥� says Charntikov. 鈥淚t will enable all of us to do research at the highest level.鈥�
听

91制片厂鈥檚 new Center of Integrated Biomedical and Bioengineering Research is funded by a five-year, $10 million Center of Biomedical Research Excellence (COBRE) grant from the National Institutes of Health.